{
    "ticker": "ZVRA",
    "name": "Zevra Therapeutics, Inc.",
    "description": "Zevra Therapeutics, Inc. is a biopharmaceutical company focused on developing novel therapies for rare and complex diseases, particularly those affecting patients with unmet medical needs. Founded in 2019 and headquartered in San Diego, California, Zevra is committed to advancing the treatment landscape for patients suffering from debilitating conditions, including rare genetic disorders and chronic pain. The company's innovative approach leverages cutting-edge research and development to create targeted therapies that address the underlying causes of diseases rather than just alleviating symptoms. Zevra's lead product candidate is designed to offer hope to patients with conditions that currently lack effective treatment options. By collaborating with leading research institutions and engaging with the patient community, Zevra aims to ensure that its developments are patient-centric and scientifically rigorous. With a dedicated team of scientists and industry veterans, Zevra is positioned to make significant contributions to the field of therapeutics, striving to improve the quality of life for patients around the world.",
    "industry": [
        "Biopharmaceuticals",
        "Healthcare"
    ],
    "headquarters": "San Diego, California, USA",
    "founded": "2019",
    "website": "https://www.zevratherapeutics.com",
    "ceo": "Jim D. G. D. D. Schaefer",
    "social_media": {
        "twitter": "https://twitter.com/ZevraThera",
        "linkedin": "https://www.linkedin.com/company/zevra-therapeutics/"
    },
    "investor_relations": "https://www.zevratherapeutics.com/investors",
    "key_executives": [
        {
            "name": "Jim D. G. D. D. Schaefer",
            "position": "CEO"
        },
        {
            "name": "Shawn T. W. M. L. W. E. McMahon",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "Zevra-01",
                "Zevra-02"
            ]
        }
    ],
    "seo": {
        "meta_title": "Zevra Therapeutics, Inc. | Innovative Solutions for Rare Diseases",
        "meta_description": "Explore Zevra Therapeutics, Inc., a biopharmaceutical company dedicated to developing novel therapies for rare and complex diseases. Learn about our innovative approach and commitment to patient care.",
        "keywords": [
            "Zevra Therapeutics",
            "Biopharmaceuticals",
            "Rare Diseases",
            "Innovative Therapies",
            "Healthcare"
        ]
    },
    "faq": [
        {
            "question": "What does Zevra Therapeutics focus on?",
            "answer": "Zevra Therapeutics focuses on developing novel therapies for rare and complex diseases."
        },
        {
            "question": "Who is the CEO of Zevra Therapeutics?",
            "answer": "Jim D. G. D. D. Schaefer is the CEO of Zevra Therapeutics, Inc."
        },
        {
            "question": "Where is Zevra Therapeutics headquartered?",
            "answer": "Zevra Therapeutics is headquartered in San Diego, California, USA."
        },
        {
            "question": "What are Zevra's main product candidates?",
            "answer": "Zevra's main product candidates include Zevra-01 and Zevra-02, targeting rare diseases with unmet medical needs."
        },
        {
            "question": "When was Zevra Therapeutics founded?",
            "answer": "Zevra Therapeutics was founded in 2019."
        }
    ],
    "competitors": [
        "VRTX",
        "SNY",
        "AMGN",
        "BMY"
    ],
    "related_stocks": [
        "GILD",
        "PFE",
        "JNJ",
        "ABBV"
    ]
}